Bismuth subsalicylate - Revision history

Ostermayer: Marked this version for translation

2026-01-06T21:25:03Z

Marked this version for translation

← Older revision		Revision as of 21:25, 6 January 2026
Line 2:		Line 2:
	<translate>		<translate>

	==Administration==		==Administration== <!--T:1-->

			<!--T:2-->
	*Type: Anti-[[Special:MyLanguage/diarrhea\|diarrhea]]l		*Type: Anti-[[Special:MyLanguage/diarrhea\|diarrhea]]l
	*Dosage Forms:		*Dosage Forms:
Line 10:		Line 11:


	==Adult Dosing==		==Adult Dosing== <!--T:3-->

			<!--T:4-->
	*[[Special:MyLanguage/Diarrhea\|Diarrhea]], gas, indigestion, heartburn, [[Special:MyLanguage/nausea\|nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily		*[[Special:MyLanguage/Diarrhea\|Diarrhea]], gas, indigestion, heartburn, [[Special:MyLanguage/nausea\|nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
	*[[Special:MyLanguage/H. pylori\|H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist		*[[Special:MyLanguage/H. pylori\|H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist


	==Pediatric Dosing==		==Pediatric Dosing== <!--T:5-->

			<!--T:6-->
	*<3y: safety/efficacy not established		*<3y: safety/efficacy not established
	*2-6y: 87mg PO q30-60m PRN		*2-6y: 87mg PO q30-60m PRN
Line 25:		Line 28:


	==Special Populations==		==Special Populations== <!--T:7-->


	===[[Special:MyLanguage/Drug pregnancy categories\|Pregnancy Rating]]===		===[[Special:MyLanguage/Drug pregnancy categories\|Pregnancy Rating]]=== <!--T:8-->

			<!--T:9-->
	*Category C, Category D in 3rd trimester		*Category C, Category D in 3rd trimester


	===Lactation risk===		===Lactation risk=== <!--T:10-->

			<!--T:11-->
	*Salicylates enter breastmilk; use with caution		*Salicylates enter breastmilk; use with caution


	===Renal Dosing===		===Renal Dosing=== <!--T:12-->

			<!--T:13-->
	*Caution: overdose may cause nephrotoxicity		*Caution: overdose may cause nephrotoxicity


	===Hepatic Dosing===		===Hepatic Dosing=== <!--T:14-->


	==Contraindications==		==Contraindications== <!--T:15-->

			<!--T:16-->
	*Allergy to class/drug		*Allergy to class/drug
	*Infectious diarrhea (fever)		*Infectious diarrhea (fever)
Line 54:		Line 61:


	==Adverse Reactions==		==Adverse Reactions== <!--T:17-->


	===Serious===		===Serious=== <!--T:18-->

			<!--T:19-->
	*Duodenal ulcer, GI hemorrhage		*Duodenal ulcer, GI hemorrhage
	*Neurotoxicity		*Neurotoxicity
Line 64:		Line 72:


	===Common===		===Common=== <!--T:20-->

			<!--T:21-->
	*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort		*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
	*Black stool, melena		*Black stool, melena
Line 78:		Line 87:


	==Pharmacology==		==Pharmacology== <!--T:22-->

			<!--T:23-->
	*Half-life: Bismuth- 21-72 days, salicylate- 2.5h		*Half-life: Bismuth- 21-72 days, salicylate- 2.5h
	*Metabolism: GI tract, liver		*Metabolism: GI tract, liver
Line 85:		Line 95:


	==Mechanism of Action==		==Mechanism of Action== <!--T:24-->

			<!--T:25-->
	*Bismuth: antimicrobial, anti-inflammatory action		*Bismuth: antimicrobial, anti-inflammatory action
	*Salicylate: antisecretory effect		*Salicylate: antisecretory effect


	==Comments==		==Comments== <!--T:26-->


	==See Also==		==See Also== <!--T:27-->

			<!--T:28-->
	*[[Special:MyLanguage/Bismuth toxicity\|Bismuth toxicity]]		*[[Special:MyLanguage/Bismuth toxicity\|Bismuth toxicity]]


	==References==		==References== <!--T:29-->

			<!--T:30-->
	https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10		https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10
	<references/>		<references/>

			<!--T:31-->
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:GI]]		[[Category:GI]]
	</translate>		</translate>

Ostermayer: Prepared the page for translation

2026-01-04T21:44:56Z

Prepared the page for translation

← Older revision		Revision as of 21:44, 4 January 2026
Line 1:		Line 1:
			<languages/>
			<translate>

	==Administration==		==Administration==
	*Type: Anti-[[diarrhea]]l
			*Type: Anti-[[Special:MyLanguage/diarrhea\|diarrhea]]l
	*Dosage Forms:		*Dosage Forms:
	*Routes of Administration: PO		*Routes of Administration: PO
	*Common Trade Names: Pepto Bismol, Maalox		*Common Trade Names: Pepto Bismol, Maalox


	==Adult Dosing==		==Adult Dosing==
	*[[Diarrhea]], gas, indigestion, heartburn, [[nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
	*[[H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist		*[[Special:MyLanguage/Diarrhea\|Diarrhea]], gas, indigestion, heartburn, [[Special:MyLanguage/nausea\|nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
			*[[Special:MyLanguage/H. pylori\|H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist


	==Pediatric Dosing==		==Pediatric Dosing==

	*<3y: safety/efficacy not established		*<3y: safety/efficacy not established
	*2-6y: 87mg PO q30-60m PRN		*2-6y: 87mg PO q30-60m PRN
Line 15:		Line 23:
	*9-12y: 262mg PO q30-60m PRN		*9-12y: 262mg PO q30-60m PRN
	*>12y: adult dose		*>12y: adult dose


	==Special Populations==		==Special Populations==
	===[[Drug pregnancy categories\|Pregnancy Rating]]===

			===[[Special:MyLanguage/Drug pregnancy categories\|Pregnancy Rating]]===

	*Category C, Category D in 3rd trimester		*Category C, Category D in 3rd trimester


	===Lactation risk===		===Lactation risk===

	*Salicylates enter breastmilk; use with caution		*Salicylates enter breastmilk; use with caution


	===Renal Dosing===		===Renal Dosing===

	*Caution: overdose may cause nephrotoxicity		*Caution: overdose may cause nephrotoxicity


	===Hepatic Dosing===		===Hepatic Dosing===


	==Contraindications==		==Contraindications==

	*Allergy to class/drug		*Allergy to class/drug
	*Infectious diarrhea (fever)		*Infectious diarrhea (fever)
	*von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia		*von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia
	*In pediatric patients; chicken pox or influenza (risk of [[Reye syndrome]])		*In pediatric patients; chicken pox or influenza (risk of [[Special:MyLanguage/Reye syndrome\|Reye syndrome]])


	==Adverse Reactions==		==Adverse Reactions==


	===Serious===		===Serious===

	*Duodenal ulcer, GI hemorrhage		*Duodenal ulcer, GI hemorrhage
	*Neurotoxicity		*Neurotoxicity
	*Renal failure		*Renal failure


	===Common===		===Common===

	*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort		*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
	*Black stool, melena		*Black stool, melena
Line 51:		Line 76:
	*Tinnitus		*Tinnitus
	*Muscle spasm		*Muscle spasm


	==Pharmacology==		==Pharmacology==

	*Half-life: Bismuth- 21-72 days, salicylate- 2.5h		*Half-life: Bismuth- 21-72 days, salicylate- 2.5h
	*Metabolism: GI tract, liver		*Metabolism: GI tract, liver
	*Excretion: Bismuth- feces, salicylate- urine		*Excretion: Bismuth- feces, salicylate- urine


	==Mechanism of Action==		==Mechanism of Action==

	*Bismuth: antimicrobial, anti-inflammatory action		*Bismuth: antimicrobial, anti-inflammatory action
	*Salicylate: antisecretory effect		*Salicylate: antisecretory effect


	==Comments==		==Comments==
Line 65:		Line 95:

	==See Also==		==See Also==
	*[[Bismuth toxicity]]
			*[[Special:MyLanguage/Bismuth toxicity\|Bismuth toxicity]]


	==References==		==References==

	https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10		https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10
	<references/>		<references/>
Line 73:		Line 106:
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:GI]]		[[Category:GI]]
			</translate>

Elcatracho: /* Administration */

2021-03-05T23:00:34Z

Administration

← Older revision		Revision as of 23:00, 5 March 2021
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: Anti[[diarrhea]]l		*Type: Anti-[[diarrhea]]l
	*Dosage Forms:		*Dosage Forms:
	*Routes of Administration: PO		*Routes of Administration: PO

ClaireLewis at 21:35, 19 September 2019

2019-09-19T21:35:43Z

← Older revision		Revision as of 21:35, 19 September 2019
Line 72:		Line 72:

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:GI]]

ClaireLewis: Created page with "==Administration== Type: Antidiarrheal Dosage Forms: Routes of Administration: PO Common Trade Names: Pepto Bismol, Maalox ==Adult Dosing== *Diarrhea, gas, indige..."

2019-09-14T15:08:36Z

Created page with "==Administration== *Type: Antidiarrheal *Dosage Forms: *Routes of Administration: PO *Common Trade Names: Pepto Bismol, Maalox ==Adult Dosing== *Diarrhea, gas, indige..."

New page

==Administration==
*Type: Anti[[diarrhea]]l
*Dosage Forms:
*Routes of Administration: PO
*Common Trade Names: Pepto Bismol, Maalox

==Adult Dosing==
*[[Diarrhea]], gas, indigestion, heartburn, [[nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
*[[H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist

==Pediatric Dosing==
*<3y: safety/efficacy not established
*2-6y: 87mg PO q30-60m PRN
*6-9y: 175mg PO q30-60m PRN
*9-12y: 262mg PO q30-60m PRN
*>12y: adult dose

==Special Populations==
===[[Drug pregnancy categories|Pregnancy Rating]]===
*Category C, Category D in 3rd trimester

===Lactation risk===
*Salicylates enter breastmilk; use with caution

===Renal Dosing===
*Caution: overdose may cause nephrotoxicity

===Hepatic Dosing===

==Contraindications==
*Allergy to class/drug
*Infectious diarrhea (fever)
*von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia
*In pediatric patients; chicken pox or influenza (risk of [[Reye syndrome]])

==Adverse Reactions==
===Serious===
*Duodenal ulcer, GI hemorrhage
*Neurotoxicity
*Renal failure

===Common===
*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
*Black stool, melena
*URI, sinusitis
*Asthenia
*Discolored tongue, taste perversion
*Headache, dizziness
*Paresthesia
*Anxiety, depression
*Tinnitus
*Muscle spasm

==Pharmacology==
*Half-life: Bismuth- 21-72 days, salicylate- 2.5h
*Metabolism: GI tract, liver
*Excretion: Bismuth- feces, salicylate- urine

==Mechanism of Action==
*Bismuth: antimicrobial, anti-inflammatory action
*Salicylate: antisecretory effect

==Comments==

==See Also==
*[[Bismuth toxicity]]

==References==
https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10
<references/>

[[Category:Pharmacology]]

Bismuth subsalicylate - Revision history

Ostermayer: Marked this version for translation

Ostermayer: Prepared the page for translation

Elcatracho: /* Administration */

ClaireLewis at 21:35, 19 September 2019

ClaireLewis: Created page with "==Administration== *Type: Antidiarrheal *Dosage Forms: *Routes of Administration: PO *Common Trade Names: Pepto Bismol, Maalox ==Adult Dosing== *Diarrhea, gas, indige..."

ClaireLewis: Created page with "==Administration== Type: Antidiarrheal Dosage Forms: Routes of Administration: PO Common Trade Names: Pepto Bismol, Maalox ==Adult Dosing== *Diarrhea, gas, indige..."